

Form PTO-1449

U.S. Department of Commerce,
Patent and Trademark Office

Atty. Docket No.

Serial No.

FEB 28 2000

3103/44139

09/029,543

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

Applicant

Eliezer Rachaman et al.

Filing Date

Group

February 26, 1998

1623

U.S. Patent Documents

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
HO	AA	2,839,536	June 17, 1958	A. O. Schnider et al	260	295	

Foreign Patent Documents

							Translation	
*Examiner Initial		Document Number	Date	Country	Class	Subclass	Yes	No
HO	AL	0,140,434	May 8, 1985	EP				
	AM	2,317,307	June 3, 1983	FR				

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	AQ	Bartus, R.T., Dean, R.L., Beer, B. and Lippa, A.S. (1982) The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science 217:408.
HO		Fisher, AS and Heldman, E. (1990) (\pm)-Cis-methyl spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): A New M1 Agonist as a Rational Treatment Strategy In Alzheimer's Disease - An overview in: Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Disease. Vol. 2: pp.309-319. (T. Nagatsu, A. Fisher and M. Yoshida, Ed.) Plenum Press, New York.
HO		Wilson, W.J. and Cook, J.A. (1994) Cholinergic Manipulations and Passive Avoidance in the Rat: Effect on Acquisition and Recall. Acta Neurobiol, Exp. Warsz. 54: 377-391.
HO		Tagliavini, F. and Pilleri, G. (1984) The Basal Nucleus of Meynert in Cerebral Aging and Degenerative Dementia's. Brain Pathology 1: 181-218.
HO		Sims, N.R., Bowen, D.M., Allen, S.J., Smith, C.C.T., Neary D., Thomas, D.J. and Davison A.N. (1983) Presynaptic Cholinergic Dysfunction in Patients with Dementia, J. Neurochem. 40: 503-509.
HO		Millard, C.B. and Broomfield C.A. (1995) Anticholinesterases: Medical Applications of Neurochemical Principles. J. Neurochem. 64: 1909-1918.
HO		Crimson, M.L. (1994) Tacrine: First Drug Approved for Alzheimer's Disease. Ann. Pharmacother. 28: 744-751.
HO		O'Brien, J.T., Eagger, S. and Levy R. (1991) Effect of tetrahydro-Aminoacridine on Liver function in Patients with Alzheimer's Disease. Age Aging 20: 129-131.
HO		Pascuzzi, R.M. (1994) The History of Myasthenia Gravis. Neurol. Clin. 12: 231-242.
HO		Arnal, F., Cote, L.J., Ginsburg, S., Lawrence G.D., Naini, A and Sano, M. (1990) Studies on New Centrally Active and Reversible Acetylcholinesterase Inhibitors. Neurochem. Res. 15: 587-591.
HO		Badawi et al., Synthesis of Some Alkyl (Aryl) Carbamic Esters of Pyridine and Piperidine and their Quaternary Salts. Evaluation as Cholinesterase Inhibitors. Egypt Journal of Chemistry, Vo. 31, no. 4, XPOO2022628 1988, Cairo, pp. 477-487.

Examiner

Date Considered

5-17-00


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

Form PTO-1449

U.S. Department of Commerce,
Patent and Trademark Office

Atty. Docket No.

Serial No.



3103/44

09/029,543

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)



Applicant

Eliezer Rachaman et al.

Filing Date

Group

February 26, 1998

1623

U.S. Patent Documents

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
HO	AA	4,439,427	March 27, 1984	Bernstein			

Foreign Patent Documents

*Examiner Initial		Document Number	Date	Country	Class	Subclass	Yes	No
	AL							

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	AQ	Sussman, J.L., Harel, M., Frolov, F., Oefner, C., Goldman, A., Tokar, L., and Silman, I., (1991) Atomic Structure of Acetylcholinesterase From Torpedo Californica: A Prototype Acetylcholine Binding Protein. Science, 253, 872-897.
HO		Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goldner, N., Hirth, C., Axelsen, P.H., Silman, I. And Sussman J.L. (1993) Quaternary Ligand Binding to Aromatic Residues in the Active Site gorge of Acetylcholinesterase. Proc. Natl. Acad. Sci. USA 90. 9031-9035.
HO		Heldman, E., Ashani Y., Raveh, L. and Rachaman, E.S. (1986) Sugar Conjugates of Pyridinium Aldoximes as Antidotes Against Organophosphate Poisoning. Carbohydrate Res. 151: 337-347.
HO		Amitai, G. Ashani, Y. Grunfeld, Y., Kalir, A., and Cohen, S. (1976) Synthesis and Properties of 2-S-[2'-(N,N-dialkylaminoethyl)thio-1,3,2-dioxaphosphorinane 2-oxide and of the Corresponding Quaternary Derivatives as Potential Non-Toxic Antiglaucoma Agents, J. Med. Chem. 19, 810-813.
HO		Finney, D.J. (1964) Statistical Methods in Biological Assays, Charles Griffin and Co., London, 2 nd Edition, P. 524.
HO		Cronnelly, R., Stanski, D.R., Miller, R.D., Lewis, M. and Sheiner B. (1980) Pyridostigmine Kinetics with and without Renal Function Clin. Pharmacol. Ther. 28: 78-81.
HO		Ranadive, S.A., Chen, A.X. and Serajuddin, A.T. (1992) Relative Lipophilicities and Structural-Pharmacological Considerations of Various Angiotensin-Converting Enzyme (ACE) Inhibitors. Pharm. Res. 9: 1480-1486.
HO		Swedberg, M.D. (1994) The Mouse Grid-Shock Analgesia Test: Pharmacological Characterization of Latency to Vocalization Threshold as an Index of Antinociception. J. Pharmacol. Ex. Ther. 269: 1021-1028.
HO		Aigner, T.G. and Mishkin M. (1986) The Effect of Physostigmine and Scopolamine on Recognition Memory in Monkeys. Behavioral and Neural Biol 45: 81-87.
HO		Elrod, L. and Boccafusco J.J. (1988) An Evaluation of Scopolamine-Induced Impairment in Two Passive Avoidance Protocols, Pharmacol. Biochem. Behav. 29: 15-21.
HO		Ellman, G.L. Courtney, K.D., Anders, V. and Featherstone, R.M., (1961) A New Rapid Colorimetric Determination of Acetylcholinesterase, Biochem. Pharmacol. 7: 88-95.
		G. Budavari (Editor): The Merck Index, 12 th Edition 1996, Merck & Co. Inc., Rahway, N.J., USA XPO02022629.

Examiner

Date Considered

5-17-00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

Form TO-1449

U.S. Department of Commerce,
Patent and Trademark Office

Atty. Docket No.

Serial No.


3103/44139

09/029,543

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)



Applicant

Eliezer Rachaman et al.

Filing Date

Group

February 26, 1998

1623

U.S. Patent Documents

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents

*Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial AQ ~~F. Tagliavini and G. Pillori, Basal Nucleus of Meynert, A Neurophysiological Study in Alzheimer's Disease, Simple Senile Dementia, Pick's Disease and Huntington's Chorea, J Neurological Sciences, 62, 243-260 (1983)~~

Examiner

Date Considered

5-17-00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.